Start EYLEA first-line. EYLEA demonstrated powerful results in patients with MEfRVO at 24 weeks—all of whom were anti-VEGF-treatment-naïve1,2

Anatomic outcomes at 24 weeks2-4

  • Primary efficacy endpoint in the VIBRANT, COPERNICUS, and GALILEO trials: % patients gaining ≥15 letters at 24 weeks from baseline vs control. See primary endpoint results.

In prespecified analyses, EYLEA significantly reduced central retinal thickness2-4

Mean Change in Central Retinal Thickness, as Measured by OCT,* at 24 Weeks From Baseline2-4,†
Graph showing mean change in central retinal thickness at 24 weeks in the VIBRANT MEfBRVO study.
Graph showing mean change in central retinal thickness at 24 weeks in the  COPERNICUS (MEfCRVO) study.
Graph showing mean change in central retinal thickness at 24 weeks in the GALILEO (MEfCRVO) study. Graph showing mean change in central retinal thickness at 24 weeks in the GALILEO (MEfCRVO) study.

Anatomic measures were not used to influence treatment decisions1

VIBRANT study design: Randomized, multicenter, double-masked, controlled study in which patients with Macular Edema following BRVO (N=181; age range: 42-94 years, with a mean of 65 years) were randomized to receive 1) EYLEA 2 mg administered every 4 weeks or 2) laser photocoagulation administered at baseline and subsequently as needed (control group).

The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.

COPERNICUS and GALILEO study designs: Randomized, multicenter, double-masked, sham-controlled studies in patients with Macular Edema following CRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either 1) EYLEA 2 mg administered every 4 weeks (monthly) for the first 6 months or 2) sham injections (control) administered every 4 weeks (monthly) for a total of 6 injections.

In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.

  • *Optical coherence tomography.
  • Last observation carried forward; full analysis set.
Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
Product support for Eylea.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
EYLEA news, events, and more.
News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2019.
  2. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049.
  3. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
  4. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278-284.